Visual Attention Span Mobilisation for Dyslexia
Maevad - Mobilisation Active de l'Empan Visuo-Attentionel Pour la Dyslexie
1 other identifier
interventional
74
1 country
55
Brief Summary
The aim of the study is to evaluate the efficiency of the medical device MAEVAD in improving the reading skills of children with dyslexia.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for not_applicable
Started Jan 2022
55 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
January 7, 2022
CompletedStudy Start
First participant enrolled
January 17, 2022
CompletedFirst Posted
Study publicly available on registry
January 21, 2022
CompletedPrimary Completion
Last participant's last visit for primary outcome
July 5, 2023
CompletedStudy Completion
Last participant's last visit for all outcomes
July 5, 2023
CompletedFebruary 28, 2024
February 1, 2024
1.5 years
January 7, 2022
February 26, 2024
Conditions
Keywords
Outcome Measures
Primary Outcomes (3)
Reading speed
Measure of reding time from texts of 122 to 152 words
10 weeks to baseline
Reading speed
Measure of reding time from texts of 122 to 152 words
18 weeks to baseline
Reading speed
Measure of reding time from texts of 122 to 152 words
26 weeks to baseline
Secondary Outcomes (14)
Reading skills
10 weeks to baseline
Reading skills
18 weeks to baseline
Reading skills
26 weeks to baseline
Orthographic skills
10 weeks to baseline
Orthographic skills
18 weeks to baseline
- +9 more secondary outcomes
Study Arms (2)
MAEVAD - DeCaLigne
EXPERIMENTALThe experimental group will first receive MAEVAD then the control therapy
DeCaLigne - MAEVAD
PLACEBO COMPARATORThe control group will first receive the control therapy then MAEVAD
Interventions
MAEVAD is a training device which aims to improve VA span as a prerequisite for learning to read. By increasing the number of distinct visual elements that can be processed simultaneously during fixation, MAEVAD is intended to improve the reading (accuracy and fluency) and spelling (lexical) performance of dyslexics who have a VA span deficit. MAEVAD is designed to be used in total autonomy by dyslexic children with a VA span disorder. The therapy takes place over 6 weeks with 5 sessions of 15 minutes per week. In order to improve compliance, the therapy has been integrated into "le Royaume d'Adelia", a serious game where the child will be able to collect materials at the end of each session that will allow him to create objects to customise a character.
DéCaLigne is an intervention programme for the discovery of calculation with the number line. The objectives are to improve numerical representations in the form of a number line and to improve addition and subtraction skills. The overall principle is to move numbers or calculation results on a number line. This training does not stimulate VA span or the phonological dimensions involved in reading. This therapy is being adapted to be used in total autonomy at home and to correspond to the MAEVAD therapy in duration (5 sessions of 15 minutes per week for 6 weeks). It has also been integrated into the "royaume d'Adelia" in order to control the motivational effect of the serious game.
Eligibility Criteria
You may qualify if:
- School children from CE2 to CM2, aged 8 to 11 years
- Dyslexic children with a VA span deficit (composite visual-attention span below the fifteenth percentile and a letter threshold above or equal to the twentieth percentile with the - - - Evadys(c) battery)
- Established diagnosis of Dyslexia
- Children whose parents/legal guardians have signed informed consent and agree to participate in the study
- Children whose first language is French or who have been educated in French since kindergarten
- Raven's Progressive Matrices score above the 20th percentile or a WISC IV or V Verbal Comprehension Index or WISC IV or V Perceptual/Fluid Reasoning Index above 85 or documented/objectifiable absence of intellectual deficit
- Child with access to a computer
- Normal or corrected vision and audition
You may not qualify if:
- Attention deficit hyperactivity disorder,dysphasia, dyspraxia, Autism Spectrum Disorder
- Neurological disorders
- Children who have missed 3 months or more of school in the current or previous year (excluding lockdown)
- Children not affiliated to a social security scheme
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Humans Matterlead
Study Sites (55)
MARTINELLI Karen
Ajaccio, 20000, France
BERARD Marine
Albertville, 73200, France
CARCEY-CADET Elise
Albertville, 73200, France
KOUASSI-PUJOL Marie
Albi, 81000, France
CLAVIER-MARCOUX Laetitia
Antibes, 06600, France
BOCCOGNANI Jordane
Argences en Aubrac, 12420, France
CHAUVET Clémence
Arles, 13200, France
CHABERT Claire
Bagnères-de-Bigorre, 65200, France
SCHMITT Véronique
Biganos, 33380, France
CRABÉ Marion
Billère, 64140, France
BIRAN Sandrine
Bordes, 64510, France
VALLERY Théoline
Brest, 29200, France
LADOUL Marine
Brive-la-Gaillarde, 19100, France
COURANT Sabrina
Cabasse, 83340, France
CONTESTI Véronique
Champagne-au-Mont-d'Or, 69410, France
MINIAC-FOURNIER Stéphanie
Château-Gontier, 53200, France
CASTERES Catherine
Digoin, 71160, France
PASQUIER Amélie
Fay-de-Bretagne, 44130, France
LEGENDRE Laure
Fontenay-sous-Bois, 94120, France
FORTIER Anne
Garches, 92380, France
BLANC Emilie
Givors, 69700, France
KRAYEM Mona
Guichainville, 27930, France
RIZK Joumana
Guichainville, 27930, France
SHAW PERRIN Anne-Sophie
Irigny, 69100, France
DE MUYNCK Solène
Lamballe, 22400, France
CADALEN Hélène
Lanmeur, 29620, France
VOLUET FROMENT Adeline
Le Chesnay, 78150, France
BERNARD-DENIS Fabienne
Le Havre, 76000, France
TERRASSON Cécile
Le Touquet-Paris-Plage, 62520, France
CALAIS Cécile
Liancourt, 60140, France
Britt
Lux, 71100, France
GOBÉ Valérie
Machecoul, 44270, France
JORDANIS Mélanie
Marignier, 74970, France
VERLOT-MORY Ludivine
Meuilley, 21700, France
MAZERAN Anne-Cécile
Miribel, 01700, France
KIS Nathalie
Montigny-le-Bretonneux, 78180, France
EMERIAU Mathilde
Nantes, 44000, France
LHUILLIER Françoise
Neufchâteau, 88300, France
LEJOSNE Julie
Paimpol, 22500, France
BRESSON Raphaëlle
Plaisir, 78370, France
BERTHELOT Florence
Plérin, 22190, France
BERTHOLOM Anne-Marine
Ploudalmézeau, 29830, France
ZIMMERMAN Amélie
Remoulins, 30210, France
CAMUS-BRUNEAU Anne
Rezé, 44400, France
KOCHEL Jeanne-Marie
Saint-Germain-en-Laye, 78100, France
VIERLING Pauline
Saint-Leu, 97416, France
LECLERC LE COADOU Rozenn
Saint-Lô, 50 000, France
NADAUD Stéphanie
Saint-Nom-la-Bretêche, 78860, France
REVERSE Christelle
Saint-Péray, 07130, France
DESCENDRE Myriam
Saint-Quentin, 02100, France
RAYNAUD LEGROS Caroline
Sainte-Anne, 97180, France
AÏT LEMKADEM Mimouna
Sartrouville, 78500, France
FRITSCH Colombine
Schiltigheim, 67300, France
CARRIQUE Pascale
Tourrettes, 83440, France
KALCK Christine
Vendenheim, 67550, France
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY CHAIR
Mélodie FOUILLEN, PhD
Humans Matter
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- DOUBLE
- Who Masked
- INVESTIGATOR, OUTCOMES ASSESSOR
- Masking Details
- The training will be performed at home. The investigators/evaluators will send a download link of the therapy to the patient's parents without knowing which therapy it corresponds to.
- Purpose
- TREATMENT
- Intervention Model
- CROSSOVER
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
January 7, 2022
First Posted
January 21, 2022
Study Start
January 17, 2022
Primary Completion
July 5, 2023
Study Completion
July 5, 2023
Last Updated
February 28, 2024
Record last verified: 2024-02
Data Sharing
- IPD Sharing
- Will not share